1. Academic Validation
  2. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors

Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors

  • J Med Chem. 2011 Mar 24;54(6):1836-46. doi: 10.1021/jm101479y.
Alexandra E Gould 1 Ruth Adams Sharmila Adhikari Kathleen Aertgeerts Roushan Afroze Christopher Blackburn Emily F Calderwood Ryan Chau Jouhara Chouitar Matthew O Duffey Dylan B England Cheryl Farrer Nancy Forsyth Khristofer Garcia Jeffery Gaulin Paul D Greenspan Ribo Guo Sean J Harrison Shih-Chung Huang Natalia Iartchouk Dave Janowick Mi-Sook Kim Bheemashankar Kulkarni Steven P Langston Jane X Liu Li-Ting Ma Saurabh Menon Hirotake Mizutani Erin Paske Christelle C Renou Mansoureh Rezaei R Scott Rowland Michael D Sintchak Michael D Smith Stephen G Stroud Ming Tregay Yuan Tian Ole P Veiby Tricia J Vos Stepan Vyskocil Juliet Williams Tianlin Xu Johnny J Yang Jason Yano Hongbo Zeng Dong Mei Zhang Qin Zhang Katherine M Galvin
Affiliations

Affiliation

  • 1 Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States. sandy.gould@mpi.com
Abstract

Inhibition of mutant B-Raf signaling, through either direct inhibition of the Enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

Figures
Products